Epstein–Barr virus vaccine

From Wikipedia, the free encyclopedia
Jump to: navigation, search

The Epstein–Barr virus vaccine is a vaccine against the Epstein–Barr virus. The vaccine is not yet available,[1] but it is in clinical trials.[2][3][4] Gp350/220[further explanation needed] is the primary target[5] and MVA-EL[further explanation needed] has been also proposed as a target.[6]

One challenge is that the Epstein–Barr virus expresses very different proteins during its lytic and its latent phases.[which?] To address this, vaccine candidates have been designed to include proteins from both phases.[7]


  1. ^ Sokal, E.M., Hoppenbrouwers, K., Vandermeulen, C. et al. (December 2007). "Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults". J. Infect. Dis. 196 (12): 1749–53. doi:10.1086/523813. PMID 18190254. 
  2. ^ Crawford, D.H., Macsween, K.F., Higgins, C.D. et al. (August 2006). "A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis". Clin. Infect. Dis. 43 (3): 276–82. doi:10.1086/505400. PMID 16804839. 
  3. ^ Elliott, S.L., Suhrbier, A., Miles, J.J. et al. (February 2008). "Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis". J. Virol. 82 (3): 1448–57. doi:10.1128/JVI.01409-07. PMC 2224445. PMID 18032491. 
  4. ^ Moutschen, M., Léonard, P., Sokal, E.M. et al. (June 2007). "Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults". Vaccine 25 (24): 4697–705. doi:10.1016/j.vaccine.2007.04.008. PMID 17485150. 
  5. ^ "WHO | Viral Cancers". Retrieved 2009-01-15. 
  6. ^ Taylor, G.S., Haigh, T.A., Gudgeon, N.H. et al. (January 2004). "Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma". J. Virol. 78 (2): 768–78. doi:10.1128/JVI.78.2.768-778.2004. PMC 368843. PMID 14694109. 
  7. ^ Lockey, T.D., Zhan, X., Surman, S., Sample, C.E., Hurwitz, J.L. (2008). "Epstein-Barr virus vaccine development: a lytic and latent protein cocktail". Front. Biosci. 13 (13): 5916–27. doi:10.2741/3126. PMID 18508632.